QNRX Schedule 13G: ADAR1 Parties Report 6.9% Stakes

Quoin Pharmaceuticals, Ltd. reported Schedule 13G ownership disclosures for certain ADAR1-related parties.

Accepted by SEC EDGAR 02/17/2026 - 08:14 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Quoin Pharmaceuticals, Ltd. reported Schedule 13G ownership disclosures for certain ADAR1-related parties. The filing shows ADAR1 Capital Management, LLC and Daniel Schneeberger each beneficially hold 58,230 American Depositary Shares (ADS), representing 6.9% of the class as of December 31, 2025. The filing states ADAR1 Capital Management GP, LLC beneficially holds 50,226 ADS (6.0%). These figures are reported based on 838,976 ADS outstanding as of November 3, 2025 as disclosed in the company prospectus. The disclosure also notes excluded amounts of ADS underlying warrants that are subject to a 4.99% beneficial ownership limitation.

Insights

Securities Compliance Counsel

Schedule 13G discloses passive/investment-adviser holdings and ownership at specific dates.

The filing lists beneficial ownership figures for ADAR1-related entities and an individual, with explicit percentages tied to November 3, 2025 outstanding ADS. It preserves the 4.99% ownership cap language for warrants.

Reviewers should note the filing characterizes relationships (investment manager, general partner, control person) and relies on the prospectus outstanding share figure; subsequent amendments or prospectus updates could change reported percentages.

Equity Ownership Analyst

ADAR1-affiliated parties hold single-digit ownership stakes but report warrant exclusions that affect potential future ownership.

The disclosed holdings are 58,230 ADS (6.9%) for two reporting persons and 50,226 ADS (6.0%) for the GP, tied to an 838,976 ADS outstanding base. The filing separately quantifies excluded ADS underlying warrants totaling up to 242,424 or 209,696 in different rows.

These warrant exclusions and the stated 4.99% beneficial ownership limit are the primary items affecting potential dilution and require tracking in subsequent filings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake does ADAR1 Capital Management report in Quoin Pharmaceuticals (QNRX)?

ADAR1 Capital Management reports beneficial ownership of 58,230 ADS, representing 6.9% of the class as of December 31, 2025. The percentage is calculated using 838,976 ADS outstanding as of November 3, 2025, per the prospectus.

How many ADS does ADAR1 Capital Management GP, LLC report owning in QNRX?

ADAR1 Capital Management GP, LLC reports beneficial ownership of 50,226 ADS, equal to 6.0% of the class. That percentage uses the prospectus figure of 838,976 ADS outstanding as of November 3, 2025.

Does the filing show any warrants or excluded securities for ADAR1-related holders?

Yes. The filing excludes ADS underlying warrants: lines reference exclusions of 242,424 and 209,696 ADS underlying warrants held by ADAR1 entities, and it states those instruments are subject to a 4.99% beneficial ownership limitation.

Why do reported percentages reference an outstanding ADS number from November 3, 2025?

Percentages in the filing are calculated using 838,976 ADS outstanding as of November 3, 2025, disclosed in the Issuer's prospectus. The filing ties ownership percentages to that explicit outstanding-share figure when reporting each holder's percent of class.

Who signed the Schedule 13G for these ADAR1-related reporting persons?

The filing is signed by Daniel Schneeberger in capacities including Manager and in his individual capacity, with signatures dated 02/17/2026, as the designated signatory for the reporting persons.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Quoin Pharmaceuticals, Ltd.

(Name of Issuer)

American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share

(Title of Class of Securities)

74907L409

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74907L409

1

Names of Reporting Persons

ADAR1 Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 58,230.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 58,230.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

58,230.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.9 %

12

Type of Reporting Person (See Instructions)

IA, OO

Comment for Type of Reporting Person: Includes (i) 50,226 American Depositary Shares ("Depositary Shares"), each representing thirty-five (35) Ordinary Shares, no par value per share ("Ordinary Shares") held by ADAR1 Partners, LP, (ii) 7,655 Depositary Shares held by Spearhead Insurance Solutions IDF, LLC, and (iii) 349 Depositary Shares held by other separately managed accounts as of December 31, 2025. Excludes 242,424 Depositary Shares underlying Warrants to Purchase Ordinary Shares Represented by American Depositary Shares or Exchange Warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 4.99% beneficial ownership limitations determined in relation to the number of Ordinary Shares underlying the Depositary Shares. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts. Based on 838,976 Depositary Shares of Quoin Pharmaceuticals, Ltd. (the "Issuer") outstanding as of November 3, 2025, reported in the Issuer's prospectus filed with the Securities and Exchange Commission on December 5, 2025.

SCHEDULE 13G

CUSIP No. 74907L409

1

Names of Reporting Persons

ADAR1 Capital Management GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 50,226.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 50,226.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

50,226.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.0 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Includes 50,226 American Depositary Shares ("Depositary Shares"), each representing thirty-five (35) Ordinary Shares, no par value per share ("Ordinary Shares") held by ADAR1 Partners, LP as of December 31, 2025. Excludes 209,696 Depositary Shares underlying Warrants to Purchase Ordinary Shares Represented by American Depositary Shares or Exchange Warrants held by ADAR1 Partners, LP, the exchange and exercise of which are subject to 4.99% beneficial ownership limitations determined in relation to the number of Ordinary Shares underlying the Depositary Shares. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. Based on 838,976 Depositary Shares of Quoin Pharmaceuticals, Ltd. (the "Issuer") outstanding as of November 3, 2025, reported in the Issuer's prospectus filed with the Securities and Exchange Commission on December 5, 2025.

SCHEDULE 13G

CUSIP No. 74907L409

1

Names of Reporting Persons

Daniel Schneeberger

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 58,230.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 58,230.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

58,230.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.9 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: Includes (i) 50,226 American Depositary Shares ("Depositary Shares"), each representing thirty-five (35) Ordinary Shares, no par value per share ("Ordinary Shares") held by ADAR1 Partners, LP, (ii) 7,655 Depositary Shares held by Spearhead Insurance Solutions IDF, LLC, and (iii) 349 Depositary Shares held by other separately managed accounts as of December 31, 2025. Excludes 242,424 Depositary Shares underlying Warrants to Purchase Ordinary Shares Represented by American Depositary Shares or Exchange Warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 4.99% beneficial ownership limitations determined in relation to the number of Ordinary Shares underlying the Depositary Shares. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts. Based on 838,976 Depositary Shares of Quoin Pharmaceuticals, Ltd. (the "Issuer") outstanding as of November 3, 2025, reported in the Issuer's prospectus filed with the Securities and Exchange Commission on December 5, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Quoin Pharmaceuticals, Ltd.
(b)	Address of issuer's principal executive offices: 42127 Pleasant Forest Court, Ashburn, VA 20148-7349
Item 2.
(a)	Name of person filing: This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"): (i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management"); (ii) ADAR1 Capital Management GP, LLC ("ADAR1 General Partner"); and (iii) Daniel Schneeberger ("Mr. Schneeberger").
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.
(c)	Citizenship: (i) ADAR1 Capital Management is a Texas limited liability company; (ii) ADAR1 General Partner is a Texas limited liability company; and (iii) Mr. Schneeberger is a citizen of Switzerland.
(d)	Title of class of securities: American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share
(e)	CUSIP No.: 74907L409
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(b)	Percent of class: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E).
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ADAR1 Capital Management, LLC

Signature:	/s/ Daniel Schneeberger
Name/Title:	Daniel Schneeberger, Manager
Date:	02/17/2026

ADAR1 Capital Management GP, LLC

Signature:	/s/ Daniel Schneeberger
Name/Title:	Daniel Schneeberger, Manager
Date:	02/17/2026

Daniel Schneeberger

Signature:	/s/ Daniel Schneeberger
Name/Title:	Daniel Schneeberger, in his individual capacity
Date:	02/17/2026

Exhibit Information

Exhibit A: Joint Filing Agreement